Hypoactive Sexual Desire Disorder
Cross-source consensus on Hypoactive Sexual Desire Disorder from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Benefits
Comparisons
Evidence quality
Highlighted claims
- Addyi and Vyleesi are the only two FDA-approved non-hormonal treatments for low sexual desire in women; both work by modulating neurotransmitter signaling rather than acting mechanically like Viagra. — Women's Sexual Health, Menopause, and Integrated Care
- HSDD affects approximately one in ten women at some point in life, and treatment is only indicated when the low desire causes personal distress. — Women's Sexual Health, Menopause, and Integrated Care
- Addyi required six years to gain FDA approval compared to six months for Viagra, illustrating a disparity in regulatory attention to women's sexual medicine. — Women's Sexual Health, Menopause, and Integrated Care
- MRI research found that women with HSDD show reduced activation in desire and reward brain regions and increased activation in inhibitory regions compared to women without the disorder. — Women's Sexual Health, Menopause, and Integrated Care
- Less than 30% of OB-GYNs are trained in sexual health, meaning most patients do not receive a full HSDD evaluation unless they find a specialist. — Women's Sexual Health, Menopause, and Integrated Care
- Addyi may also produce a satiety-like effect via dopamine pathways, with some women losing up to 5% of body weight. — Women's Sexual Health, Menopause, and Integrated Care